Sourav Bandyopadhyay, PhD

Associate Professor
Bioengineering
+1 415 476-3425
Research Description: 

Our lab focuses on methods to map pathway rewiring in cancer. Our major goal is to understand at the systems level how the biological networks within cancer cells are fundamentally different from that in normal cells. Using our technologies, we intend to develop platforms for the rational application of personalized medicine and design of combination cancer therapies.

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
None
Research Summary: 
Computational and experimental approaches to guide the development of new precision medicines for cancer

Websites

Publications: 

Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models.

Blood

CHI-HENG WU, Chen-Yen Yang, Linlin Wang, Hua-Xin Gao, Rakhshandehroo Taha, Shervin Afghani, Laura Pincus, Ronald Balassanian, James Rubenstein, Ryan Gill, Sourav Bandyopadhyay, Frank McCormick, Mark Moasser, Weiyun Z. Ai

Targeting the evolution of drug resistance in lung cancer.

Molecular & cellular oncology

Shah KN, Bandyopadhyay S

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

Nature medicine

Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S

P1.13-10 Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer.

Journal of Thoracic Oncology

K. Shah, C. Blakely, T. Bivona, S. Bandyopadhyay